PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 10, 2025Haematologica1 citationsOpen Access

Survival Outcomes After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Patients by Age

The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients

View Full Paper
Ask AI
Bookmark
Share

Authors

SMShohei MizunoLGLuuk GrasLBLaurien Baaij

Discussion

Loading...

Member takes

Overview

Analysis reveals age impacts survival and non-relapse mortality in multiple myeloma patients, suggesting further considerations for treatment decisions.

Key Points

  • Older age significantly affects overall survival and progression-free survival after autologous hematopoietic cell transplantation.
  • At three years, overall survival probabilities range from 85.9% for ages 18-39 to 74.8% for ages ≥75 (p<0.001).
  • Multivariable analyses identified age as a risk factor for overall survival and non-relapse mortality but not for excess mortality.
  • Findings highlight that advanced age should not automatically exclude patients from receiving autologous hematopoietic cell transplantation.

Cite This Study

Mizuno et al. (2025) studied this question.

synapsesocial.com/papers/68c1a26954b1d3bfb60dda0chttps://doi.org/10.3324/haematol.2025.288041
View Full Paper
Ask AI
Bookmark
Share